Depomed flies on favorable Gralise infringement ruling
This article was originally published in Scrip
Executive Summary
Shares of Depomed raced up about 15% in morning trading on 19 August after the company said it had prevailed in its patent infringement suit involving its postherpetic neuralgia treatment Gralise (gabapentin) against Actavis, which is seeking to market a generic version of the drug in the US.